Michael Hund is the CEO of EB Research Partnership (EBRP), a trailblazing medical research organization focused on curing Epidermolysis Bullosa (EB), a life-threatening genetic skin disease. Under his leadership EBRP has accelerated the landscape from 2 to over 40 clinical trials and via their award winning venture philanthropy methodology funded the first FDA approved treatment for EB in 2023, the first ever topical gene therapy.
Information
- Show
- Published10 November 2023 at 19:03 UTC
- Length24 min
- RatingClean